September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
July 2024 in “Journal of Investigative Dermatology” Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
3 citations
,
May 2022 in “JAAD case reports” A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib maintains significant hair regrowth in severe alopecia areata over three years.
36 citations
,
May 2005 in “BMC dermatology” DPCP is effective for treating severe alopecia areata, but relapse is common.
4 citations
,
September 2022 in “Dermatologic Therapy” Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.
March 2026 in “International Journal of Biological Macromolecules” Recombinant Filaggrin-2 microneedles effectively promote hair growth and repair in hair loss.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
11 citations
,
September 2014 in “International Journal of Molecular Sciences” Mycophenolate helps reverse hair loss effects caused by IFN-γ by activating a key hair growth pathway.
July 2025 in “Journal of Drug Delivery Science and Technology” Hydrogel microneedles with special nanoparticles and growth factor improve hair growth better than minoxidil for hair loss treatment.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
November 2023 in “International Journal of Pharmaceutics” The new delivery system improves treatment for hair loss by enhancing drug absorption and effectiveness.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Both treatments help hair regrowth, but Botulinum Toxin-A has fewer side effects.
September 2022 in “International Journal of Trichology” Both microneedling and injections are equally effective for treating alopecia areata.